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Abstract
Background: Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstrictor.
The optimal albumin dose remains poorly characterized. This meta-analysis aimed to determine the impact of
albumin dose on treatment outcomes.
Methods: Clinical studies of type 1 hepatorenal syndrome treatment with albumin and vasoconstrictor were
sought. Search terms included: hepatorenal syndrome; albumin; vasoconstrictor; terlipressin; midodrine; octreotide;
noradrenaline; and norepinephrine. A meta-analysis was performed of hepatorenal syndrome reversal and survival in
relation to albumin dose.
Results: Nineteen clinical studies with 574 total patients were included, comprising 8 randomized controlled trials, 8
prospective studies and 3 retrospective studies. The pooled percentage of patients achieving hepatorenal syndrome
reversal was 49.5 % (95 % confidence interval, 40.0-59.1 %). Increments of 100 g in cumulative albumin dose were
accompanied by significantly increased survival (hazard ratio, 1.15; 95 % confidence interval, 1.02-1.31; p = 0.023). A
non-significant increase of similar magnitude in hepatorenal syndrome reversal was also observed (odds ratio, 1.15;
95 % confidence interval, 0.97-1.37; p = 0.10). Expected survival rates at 30 days among patients receiving cumulative
albumin doses of 200, 400 and 600 g were 43.2 % (95 % confidence interval, 36.4-51.3 %), 51.4 % (95 % confidence
interval, 46.3-57.1 %) and 59.0 % (95 % confidence interval, 51.9-67.2), respectively. Neither survival nor hepatorenal
syndrome reversal was significantly affected by vasoconstrictor dose or type, treatment duration, age, baseline serum
creatinine, bilirubin or albumin, baseline mean arterial pressure, or study design, size or time period.
Conclusions: This meta-analysis suggests a dose–response relationship between infused albumin and survival
in patients with type 1 hepatorenal syndrome. The meta-analysis provides the best current evidence on the
potential role of albumin dose selection in improving outcomes of treatment for type 1 HRS and furnishes
guidance for the design of future dose-ranging studies.
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Background
Hepatorenal syndrome (HRS) is a form of functional
severe renal failure in patients with advanced liver cir-
rhosis. This life-threatening complication results from
marked renal vasoconstriction and its consequent re-
duced renal perfusion and glomerular filtration rate.
The diagnosis is based mainly on excluding other
causes of renal impairment and demonstrating lack of
response to a 2-day course of volume expansion [1].
Based on clinical features and prognosis, HRS is classi-
fied into type 1 and 2. Type 1 HRS presents as acute
renal failure characterized by at least a two-fold in-
crease in serum creatinine to a level greater than
2.5 mg/dL in less than 2 weeks. The prognosis is poor,
with survival averaging 11 days in patients with un-
treated type 1 HRS [2]. However, this condition is po-
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be improved by prompt medical treatment in about half
of the patients developing type 1 HRS.
As a first-line therapy of type 1 HRS, both the Inter-
national Ascites Club (IAC) and the American Association
for the Study of Liver Diseases (AASLD) recommend a
combination of vasoconstrictors and albumin infusion
[3, 4]. The additive effects provided by vasoconstrictors
and albumin infusion are thought to improve outcomes
vs. monotherapy with either agent. The vasopressors
shown in clinical studies to be effective have been pri-
marily either terlipressin, a vasopressin analogue, or the
α-agonist midodrine combined with octreotide [3, 4].
Noradrenaline is another option. Patients are typically
titrated with escalating vasoconstrictor doses until a re-
sponse to treatment is achieved [3, 4].
Albumin has generally been administered in fixed doses.
The IAC guidelines [3] recommend an albumin dose of
1 g/kg on the first day up to a maximum of 100 g followed
by 20–40 g/day. Nevertheless, dose optimization studies
have not been reported, and questions remain about the
most effective albumin regimen. Meta-analysis provides
a long established and commonly applied methodology
for quantitatively combining dose–response data across
studies [5, 6]. This meta-analysis was designed to evalu-
ate the impact of albumin dose selection on outcomes
of type 1 HRS.
Patients and methods
Study selection
Clinical studies were sought which evaluated albumin
infusion and concomitant vasoconstrictor to treat pa-
tients with type 1 HRS. Case reports and case series
were excluded. Data must have been available on HRS
reversal and/or survival time. Albumin and vasocon-
strictor dose and duration of treatment must have been
reported. Studies of ornipressin, vasopressin, monotherapy
with octreotide, and furosemide co-therapy were not con-
sidered. No restrictions were placed on study design, prior
publication, language of reporting or time period. Study
eligibility was determined by all three investigators.
While randomized trials were sought, in no case were
type 1 HRS patients randomly assigned to different al-
bumin doses. Thus, although random allocation might
signify higher study quality, it could not serve to minimize
potential confounding in this meta-analysis. Nonrando-
mized studies were also sought. Inclusion of such stud-
ies in meta-analyses, where feasible, has been advocated
because they can increase statistical power as well as
allowing important clinical questions to be addressed
for which randomized trial data are unavailable or inad-
equate [7, 8]. Nonrandomized studies may be more vul-
nerable to biases, but nonetheless empirical studies
have shown treatment effects to be similar between
randomized and nonrandomized studies [9, 10]. Based
upon a representative cross-sectional sample of 300 pub-
lished meta-analyses, nonrandomized studies were eligible
for inclusion in 40 % of all meta-analyses [11].
Search strategy
Sources searched for eligible studies were MEDLINE,
EMBASE, the Cochrane Library, the ClinicalTrials.gov
web site, the abstract databases from major meetings
in hepatology and gastroenterology, texts indexed by
Google, reference lists of publications on HRS, and online
tables of contents for hepatology and gastroenterology
journals. Computer search terms included hepatorenal
syndrome; albumin; vasoconstrictor; terlipressin; mido-
drine; octreotide; noradrenaline; and norepinephrine; as
well as roots and variants of those terms. A representa-
tive MEDLINE search strategy is outlined in Table 1.
Data extraction
Details of candidate study reports were scrutinized to
avoid inclusion of redundant data appearing in mul-
tiple articles. Data were extracted for year of report-
ing; study design; criteria for diagnosis of HRS and
for HRS reversal; numbers of patients; age; baseline
serum creatinine, bilirubin and albumin; creatinine in-
crease after diagnostic volume expansion; frequencies
of ascites, spontaneous bacterial peritonitis, infection,
gastrointestinal bleeding and hepatocellular carcinoma;
baseline mean arterial pressure, heart rate, hemoglobin,
white blood cells, and platelets; albumin and vasocon-
strictor dose; concentration of infused albumin; duration
of treatment; HRS reversal; adverse events due to albumin
administration and survival time. In controlled investiga-
tions data were extracted only for study arms fulfilling the
eligibility criteria of the meta-analysis. When data for pa-
tients with either type 1 or 2 HRS were presented in segre-
gated form, only the type 1 data were extracted. Type 1/2
HRS outcome data reported only in the aggregate were
excluded. Individual patient serum creatinine and sur-
vival time data were captured as required by computer
digitization from graphic displays in the study reports.
Table 1 Representative MEDLINE search strategy
Set Query
1 “hepatorenal syndrome”
2 albumins/therapeutic use [mh]
3 vasoconstrictor* OR terlipressin OR midodrine
OR octreotide OR noradrenaline OR norepinephrine
4 lypressin/therapeutic use [mh]
5 adrenergic alpha-agonists/therapeutic use [mh]
6 #3 OR #4 OR #5
7 humans [mh]
8 #1 AND #2 AND #6 AND #7
Salerno et al. BMC Gastroenterology  (2015) 15:167 Page 2 of 11
Data extraction was carried out independently by two
investigators, and differences of interpretation were dis-
cussed and resolved. When necessary, included study
investigators were contacted for supplementary unpub-
lished data.
Ethical approval and consent
This investigation was limited to statistical analysis of
data collected in previous clinical studies and did not
constitute medical research involving human subjects
or research on identifiable human material and data.
Accordingly, ethics committee approval and patient in-
formed consent were not applicable.
Standards of reporting
This meta-analysis was reported in conformity with the
Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) guidelines [7]. A completed MOOSE checklist
is included in Additional file 1.
Data availability
The data sets supporting the results of this meta-analysis
are provided in Additional file 2 as working R code (The
R Foundation for Statistical Computing, Vienna, Austria).
Raw data, function definitions and intermediate computa-
tions are included.
Statistical analysis
The hypothesis of the meta-analysis was that outcomes
of type 1 HRS treatment vary significantly as a function
of albumin dose. The endpoints were HRS reversal, de-
fined as reduction in serum creatinine to < 1.5 mg/dL or
¶ 1.5 mg/dL, and survival. If other HRS reversal criteria
were applied in the reports of included studies, the individ-
ual patient serum creatinine data were used to reclassify
the patients in accordance with the < 1.5 mg/dL criterion
of the meta-analysis.
It was anticipated that variation in albumin doses
administered would result in significant heterogeneity
of outcomes between patient groups. Heterogeneity was
assessed by Cochran Q test and the I2 statistic [12]. In
order to accommodate expected heterogeneity, random
effects models were used to combine results quantitatively
across studies. Albumin dose was analyzed as one source
of heterogeneity. Also, in accordance with the MOOSE
guidelines [7], an array of other variables were examined
as potential sources of heterogeneity.
Since patients with type 1 HRS are subject to rapidly
increasing mortality, crude mortality data are vulnerable
to bias resulting from differences in duration of follow-
up, and only survival data with accounting for time at
risk were used in the meta-analysis. In the analysis of
survival, patients were censored at the time of loss to
follow-up or supervening interventions such as liver
transplantation or transjugular intrahepatic portosyste-
mic shunt insertion. Individual study group survival
curves were analyzed by the Kaplan-Meier product-
limit method. The effects of albumin dose and other
variables on HRS reversal and survival were analyzed
by mixed effects logistic regression and Cox propor-
tional hazards regression, respectively, with study as a
random effect in both cases. Study quality and publi-
cation bias were assessed by sensitivity analyses of study
design and size, respectively. Statistical analyses were con-
ducted using R version 3.0.2 software.
Results
Included studies
The selection process for the meta-analysis is shown in
Fig. 1. Of 161 candidate clinical study reports identified,
38 were excluded at the screening stage, most often be-
cause they were review articles. After detailed examin-
ation of the remaining 123 reports, 101 were excluded,
again most frequently since they reviewed the literature
rather than providing original data.
Upon determination that they fulfilled all eligibility
criteria 19 clinical studies published from 1999 to 2012
with 574 total patients were included in the meta-
analysis [1, 13–30]. The median number of patients per
study was 24 (interquartile range, 12–44). Data from 4
161 clinical study reports
identified and screened
101 reports excluded after detailed examination
36 review article
9 extracorporeal albumin dialysis
8 commentary
7 not HRS type 1
6 no concomitant albumin/vasoconstrictor
5 incomplete dose data
5 case series
5 meta-analysis
4 ineligible vasoconstrictor
4 large-volume paracentesis
3 HRS type 1/2 data aggregated
3 no data for endpoints of meta-analysis
2 clinical guidelines
2 furosemide
1 not HRS type 1
1 pharmacoeconomic study
Reports Reason Excluded
38 reports excluded after screening
20 review article
6 extracorporeal albumin dialysis
3 no concomitant albumin/vasoconstrictor
2 not HRS type 1
2 meta-analysis
2 commentary
1 no data for endpoints of meta-analysis
1 case series
1 clinical guidelines
Reports Reason Excluded
123 reports examined in detail
19 clinical studies in
22 reports included
Fig. 1 Clinical study selection process. Abbreviation: HRS,
hepatorenal syndrome
Salerno et al. BMC Gastroenterology  (2015) 15:167 Page 3 of 11
of the studies [14, 16, 19, 21] were also included in 3 sep-
arate publications focused on predictors of response to
treatment [31–33]. Eight of the 19 included studies were
randomized controlled trials, 8 prospective studies and 3
retrospective studies (Tables 2 and 3). Two arms of 4
randomized trials and of one prospective study were
included, and thus 24 total patient groups were repre-
sented in the meta-analysis (Tables 2 and 3).
In all 19 studies type 1 HRS was diagnosed according
to the IAC criteria [3, 34]. Diagnostic volume expansion
was with albumin in 6 studies [1, 17, 18, 22, 23, 30], sa-
line in 3 [20, 25, 28], both in 2 [13, 15] and either or
both in one [21]. Unspecified colloid or crystalloid was
utilized for diagnostic volume expansion in one study
[24], while type of fluid infused for that purpose was
unspecified in 5 studies [14, 16, 19, 27, 29].
Treatment
The mean cumulative dose of albumin administered
was < 200 g in 7 of the patient groups (29.2 %), 200–400 g
in 10 (41.6 %) and > 400 g in 7 (29.2 %), as shown in
Table 2. The daily albumin dose averaged < 30 g in 10
groups (41.6 %), 30–40 g in 7 (29.2 %) and > 40 g in
7 (29.2 %). The concentration of albumin infused was
20 % in all 10 groups for which specified.
Albumin was co-administered with terlipressin in 15
groups (62.5 %), midodrine/octreotide in 5 (20.8 %) and
noradrenaline in 4 (16.7 %). The mean duration of albu-
min/vasoconstrictor therapy was < 8 d in 10 groups
(41.7 %), 8–14 d in 9 (37.5 %) and > 14 d in 5 (20.8 %).
Patients
Five baseline patient characteristics were consistently re-
ported for the study groups: age, serum concentrations of
creatinine, bilirubin and albumin, and mean arterial pres-
sure (Table 3). Other baseline variables were more sparsely
reported. Data were presented on the baseline frequency of
infection for 16 groups, ascites for 13, gastrointestinal bleed-
ing for 9, hepatocellular carcinoma for 8, and spontaneous
bacterial peritonitis for 2. Patients exhibiting an increase in
Table 2 Treatment regimena
Study Patients Albumin dose (g) Vasoconstrictor Treatment duration (d)
Randomized Type Dose (mg)
Alessandria et al., 2007 [18] 5 350 terlipressin 55 7.6
4 406 noradrenaline 188 7.2
Martín-Llahí et al., 2008 [19] 17 190 terlipressin 66 7.0
Neri et al., 2008 [20] 26 836 terlipressin 36 19.0
Sanyal et al., 2008 [21] 56 304 terlipressin 28 6.3
Sharma et al., 2008 [22] 20 243 terlipressin 47 8.1
20 234 noradrenaline 187 7.8
Silawat et al., 2011 [27] 30 88 terlipressin 10 7.0
Singh et al., 2012 [29] 23 156 terlipressin 24 7.8
23 186 noradrenaline 132 9.3
Tavakkoli et al., 2012 [30] 9 720 midodrine/octreotide 270/5.4 18.0
6 720 noradrenaline 146 18.0
Prospective
Angeli et al., 1999 [13] 5 300 midodrine/octreotide 630/9.6 20.0
Uriz et al., 2000 [14] 6 358 terlipressin 48 10.6
Mulkay et al., 2001 [15] 12 200 terlipressin 72 26.0
Wong et al., 2004 [17] 14 700 midodrine/octreotide 35/8.4 14.0
Muñoz et al., 2009 [23] 13 592 terlipressin 41 9.6
Rivero et al., 2010 [26] 41 250 terlipressin 63 7.0
Salerno et al., 2011 [1] 40 235 terlipressin 63 8.7
24 235 midodrine/octreotide 207/2.8 8.7
Narahara et al., 2012 [28] 8 162 terlipressin 18 6.3
Moreau et al., 2002 [16] 99 433 terlipressin 36 11.4
Skagen et al., 2009 [24] 49 368 midodrine/octreotide 222/3.6 8.4
von Kalckreuth et al., 2009 [25] 24 193 terlipressin 27 7.1
aIndicated doses are mean cumulative values.
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serum creatinine after diagnostic volume expansion were
enumerated for one group. Measurements were reported of
heart rate for 11 groups, hemoglobin and platelets for 3
each and white blood cells for 2.
In 7 reports [16, 17, 22, 23, 29, 32, 33] baseline pa-
tient data were stratified according to treatment re-
sponse. Significant differences for the 5 variables in
Table 3 were infrequent and inconsistent. Mean arter-
ial pressure was significantly higher among responders
than nonresponders in 2 reports [22, 29] as also was
serum albumin in one of those 2 reports [29]. Responders
were significantly younger than nonresponders in one re-
port [16], while baseline bilirubin was lower among re-
sponders in another report [32].
HRS reversal
In 15 studies the criterion for HRS reversal was a decline
in serum creatinine to < 1.5 mg/dL or the reported data
allowed classification of the patients in accordance with
that cutoff. In 3 studies the criterion was ¶ 1.5 mg/dL.
No criterion was indicated for one study assessing renal
function and survival but not HRS reversal per se [24].
Data on HRS reversal were available for 23 patient
groups with 525 total patients (Table 4). The pooled per-
centage of patients attaining HRS reversal was 49.5 %
with a 95 % confidence interval (CI) of 40.0-59.1 %
(Fig. 2). No significant differences in HRS reversal could
be detected in relation to any of the treatment, patient
and study variables listed in Table 4.
Table 3 Baseline patient characteristicsa
Study Vasoconstrictor Age (y) Serum concentrationb MAP (mm Hg)
Randomized Creatinine Bilirubin Albumin
Alessandria et al., 2007 [18]c terlipressin 55.0 (6.9) 2.5 (1.0) 5.1 (3.5) 3.0 (0.3) 74.0 (10.4)
noradrenaline 56.0 (9.5) 2.3 (0.6) 4.1 (3.2) 3.0 (0.6) 71.0 (6.3)
Martín-Llahí et al., 2008 [19]c terlipressin 59.0 (10.0) 3.6 (1.5) 18.1 (19.1) 3.0 (0.7) 73.0 (10.0)
Neri et al., 2008 [20] terlipressin 59.0 (4.0) 2.8 (1.1) — 2.7 (0.3) 82.0 (2.0)
Sanyal et al., 2008 [21] terlipressin 50.6 (10.5) 4.0 (2.2) 15.0 (13.6) 2.6 (0.8) 75.5 (11.4)
Sharma et al., 2008 [22] terlipressin 47.8 (9.8) 3.0 (0.5) 7.6 (9.8) 2.6 (0.6) 81.4 (11.4)
noradrenaline 48.2 (13.4) 3.3 (1.3) 5.2 (6.8) 2.4 (0.4) 78.2 (5.3)
Silawat et al., 2011 [27] terlipressin — 3.0 (1.3) 3.4 (2.1) 2.4 (0.7) 67.6 (16.4)
Singh et al., 2012 [29] terlipressin 51.4 (11.6) 3.3 (0.7) 4.0 (2.6) 2.8 (0.4) 64.7 (11.9)
noradrenaline 48.3 (11.6) 3.1 (0.7) 4.7 (5.7) 2.8 (0.2) 65.2 (10.2)
Tavakkoli et al., 2012 [30]c midodrine/octreotide 52.9 (12.6) 2.6 (0.8) 11.6 (12.2) 2.6 (0.3) 69.8 (7.1)
noradrenaline 52.0 (12.9) 2.6 (0.7) 8.0 (7.8) 2.7 (0.2) 73.4 (6.7)
Prospective
Angeli et al., 1999 [13] midodrine/octreotide 62.0 (6.7) 5.0 (2.0) 4.3 (2.9) 3.0 (0.2) 75.9 (6.7)
Uriz et al., 2000 [14]c terlipressin 54.0 (11.0) 3.9 (2.1) 14.0 (18.0) 3.2 (0.6) 68.0 (6.0)
Mulkay et al., 2001 [15] terlipressin 53.5 (5.1) 3.4 (0.5) 6.2 (6.3) 2.9 (0.3) 76.0 (5.0)
Wong et al., 2004 [17] midodrine/octreotide 55.2 (7.9) 2.9 (1.2) 3.0 (1.6) 3.2 (1.0) 80.6 (14.7)
Muñoz et al., 2009 [23] terlipressin 54.2 (21.5) 3.3 (5.9) — — 69.6 (29.6)
Rivero et al., 2010 [26] terlipressin — — — — —
Salerno et al., 2011 [1] terlipressin 62.0 (7.6) 3.2 (1.2) 15.1 (10.1) 2.8 (0.4) 80.4 (8.2)
midodrine/octreotide 62.0 (5.9) 3.2 (0.9) 15.1 (7.8) 2.8 (0.3) 80.4 (6.4)
Narahara et al., 2012 [28] terlipressin 59.1 (11.8) 3.0 (0.8) 9.4 (7.6) 2.5 (0.4) 74.0 (14.0)
Retrospective
Moreau et al., 2002 [16] terlipressin 56.0 (10.0) 2.9 (1.1) 11.8 (12.9) 2.8 (0.7) 78.0 (20.0)
Skagen et al., 2009 [24] midodrine/octreotide 52.7 (10.6) 2.5 (1.3) — — —
von Kalckreuth et al., 2009 [25] terlipressin 51.8 (9.4) — — — —
aIndicated values are mean (standard deviation).
bSerum creatinine and serum bilirubin in mg/dL and serum albumin in g/dL.
cIndicated baseline data reported only in the aggregate for types 1 and 2 HRS. However, outcome data (HRS reversal/survival) were reported separately for
patients with type 1HRS, and only those separate outcome data for type 1 HRS were used in the meta-analysis.
Abbreviation: HRS, hepatorenal syndrome; MAP, mean arterial pressure.
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Survival
Time of survival data were reported for 15 patient groups
with 377 total patients (Fig. 3). At 30 days, pooled survival
was 50.6 % (CI, 45.5-56.3 %).
Increments of 100 g in cumulative albumin dose were
associated with a significant increase in survival (hazard
ratio, 1.15; CI, 1.02-1.31; p = 0.023; Table 4). An associ-
ation of similar magnitude and direction was also ob-
served for 10 g increments in mean daily albumin dose;
however, that association did not reach statistical sig-
nificance (hazard ratio, 1.20; CI, 0.99-1.46); p = 0.064).
No significant survival differences were observed with
respect to any of the other tested variables (Table 4).
From the Cox regression model expected survival
curves were constructed for several cumulative albu-
min doses (Fig. 4). Among patients receiving 200, 400
and 600 g cumulative doses the expected percentages
surviving at 30 days were 43.2, 51.4 and 59.0 %,
respectively.
Discussion
A number of previous meta-analyses have examined
pharmacologic treatment of HRS [35–39]. However,
they all focused on the effectiveness of vasoconstrictor
treatment, and indeed only one even required concomi-
tant albumin as an inclusion criterion [38]. The present
meta-analysis is the first to investigate the impact of albu-
min dose on treatment outcomes of type 1 HRS.
The outlook for type 1 HRS patients has improved
markedly with the advent of pharmacological therapy
employing vasoconstrictors and albumin in the last
15 years. This approach has provided for some patients
a successful bridge to liver transplantation, the only de-
finitive treatment for HRS [3, 40–42]. The goal is to re-
verse in a very short time window the kidney failure
before it leads to irreversible structural renal damage
and death. However, only an estimated 40 to 60 % of
patients respond to the combination therapy with re-
versal of kidney failure [43, 44]. Consequently, ways to
improve the efficacy of the combined treatment and to
identify predictors of response are currently active areas
of investigation [31–33].
While the primary focus for optimizing therapy has
been on the dose, duration and mode of administration
for the different vasoconstrictors [45, 46], albumin is
recognized as an integral part of the therapy and
optimization of the albumin regimen could also poten-
tially lead to improved response and survival. While the
Table 4 Effect of treatment, patient and study variables on outcome
Variablea HRS Reversal Survival
Treatment Groups Odds Ratio (CI) p Groups Hazard Ratio (CI) p
Albumin dose (g) 23 1.15 (0.97-1.37) 0.10 15 1.15 (1.02-1.31) 0.023
Vasoconstrictor dose (mg) 23 0.86 (0.61-1.20) 0.38 15 1.28 (0.91-1.79) 0.16
Vasoconstrictor type 23 0.90 (0.51-1.57) 0.70 15 0.89 (0.49-1.59) 0.69
Treatment duration (d) 23 1.15 (0.46-2.89) 0.76 15 1.63 (0.84-3.13) 0.15
Patient
Age (y) 21 0.99 (0.39-2.51) 0.99 15 1.37 (0.78-2.42) 0.28
Serum creatinine (mg/dL) 21 0.56 (0.31-1.01) 0.054 15 0.93 (0.52-1.65) 0.79
Serum bilirubin (mg/dL) 19 0.76 (0.37-1.57) 0.46 12 1.13 (0.65-1.94) 0.67
Serum albumin (g/dL) 20 1.11 (0.41-2.99) 0.83 13 1.58 (0.80-3.12) 0.19
MAP (mm Hg) 21 1.02 (0.41-2.55) 0.97 14 1.24 (0.71-2.15) 0.45
Study
Design
Prospective 11 1.24 (0.36-4.29) 0.74 7 1.05 (0.55-1.99) 0.88
Randomized 21 1.25 (0.56-2.84) 0.59 13 0.85 (0.44-1.64) 0.62
Number of patients 23 0.68 (0.45-1.04) 0.07 15 0.95 (0.68-1.33) 0.75
Year reported 23 1.38 (0.56-3.40) 0.48 15 0.84 (0.44-1.59) 0.58
aAlbumin dose was analyzed per 100 g increment in cumulative dose. To allow comparisons between doses of different vasoconstrictors on a common scale,
cumulative doses of each vasoconstrictor were standardized, with the values for midodrine and octreotide averaged. In the analysis of vasoconstrictor type,
terlipressin was compared with other vasoconstrictors. To normalize data distributions, treatment duration and number of patients were log transformed. Patient
variables were stratified by values above cutoffs equaling the pooled midpoint between the means of responders and nonresponders among the included studies
as compared with lower values. The cutoffs were 53 y for age, 3.1 mg/dL for serum creatinine, 8.3 mg/dL for serum bilirubin, 2.8 g/dL for serum albumin, and
76 mm Hg for MAP. Prospective studies were compared with retrospective studies as the reference category, randomized studies with nonrandomized studies,
and studies reported after 2005 with those before. Available data for HRS reversal were from 23 patient groups with 525 total patients and for time of survival
from 15 patient groups with 377 total patients.
Abbreviations: HRS, hepatorenal syndrome; MAP, mean arterial pressure.
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regimen of albumin administered has not been the pri-
mary endpoint of any individual study, the numerous cur-
rently available reports on the use of vasoconstrictors and
albumin in type 1 HRS patients allow the examination of
treatment outcomes as a function of the albumin regimen
over a substantial range of cumulative albumin doses.
Across all available studies included in the meta-analysis
the overall rate of HRS reversal in response to co-therapy
with albumin and vasoconstrictor was 49.5 %. This is the
most comprehensive and precise estimate of HRS reversal
rate thus far and confirms the accuracy of prior estimates.
Importantly, while a variety of definitions for HRS reversal
have been adopted in individual studies, the estimated
rate in the meta-analysis was based upon a single
homogeneous criterion of serum creatinine reduction
to < 1.5 mg/dL or ¶ 1.5 mg/dL. This strength of the
meta-analysis was made possible by extraction and use
of individual patient serum creatinine data.
While 100 g increments in cumulative albumin dose
were associated with increased HRS reversal rate (Table 4),
this association did not reach statistical significance
(p = 0.10). Nor did any other evaluated treatment,
patient or study variable show a significant effect on HRS
reversal. Some differences in baseline patient variables re-
lated to treatment response were observed in individual
studies, although these were infrequent and inconsistent.
The meta-analysis revealed significant improvement in
survival associated with 100 g increments in cumulative
albumin dose (Table 4). Over the range of cumulative al-
bumin doses between 200 and 600 g, a range commonly
administered among the included studies, expected sur-
vival at 30 days increased from 43.2 to 59.0 % (Fig. 4).
The robustness of these findings is supported by the
relatively large sample size of 377 patients at risk for
death; the extraction of individual patient survival time
data and analysis of those data by methodology that fully
accounts for time at risk; and the ability to rule out con-
founding by an array of treatment, patient and study var-
iables. The association between increasing cumulative
albumin dose and decreasing mortality could not be ex-
plained by vasoconstrictor dose or type, treatment dur-
ation, age, baseline serum creatinine, bilirubin or albumin,
baseline mean arterial pressure, or study design, size or
time period. On the other hand, the investigations
Study Vasoconstrictor Patient %s HRS Reversal (CI) % Wgt.
Reversal Total
Angeli et al., 1999 [13] midodrine/octreotide 0 05 .0 (0.0-52.2) 0.1
Uriz et al., 2000 [14] terlipressin 5 6 83.3 (53.5-100.0) 3.7
Mulkay et al., 2001 [15] terlipressin 5 12 41.7 (13.8-69.6) 3.9
Moreau et al., 2002 [16] terlipressin 27 99 27.3 (18.5-36.0) 6.2
Wong et al., 2004 [17] midodrine/octreotide 10 14 71.4 (47.8-95.1) 4.4
Alessandria et al., 2007 [18] terlipressin 4 5 80.0 (44.9-100.0) 3.1
noradrenaline 3 4 75.0 (32.6-100.0) 2.5
Martín-Llahí et al., 2008 [19] terlipressin 5 17 29.4 (7.8-51.1) 4.7
Neri et al., 2008 [20] terlipressin 21 26 80.8 (65.6-95.9) 5.5
Sanyal et al., 2008 [21] terlipressin 19 56 33.9 (21.5-46.3) 5.8
Sharma et al., 2008 [22] terlipressin 8 20 40.0 (18.5-61.5) 4.7
noradrenaline 10 20 50.0 (28.1-71.9) 4.6
Muñoz et al., 2009 [23] terlipressin 4 13 30.8 (5.7-55.9) 4.2
von Kalckreuth et al., 2009 [25] terlipressin 15 24 62.5 (43.1-81.9) 5.0
Rivero et al., 2010 [26] terlipressin 22 41 53.7 (38.4-68.9) 5.5
Salerno et al., 2011 [1] terlipressin 12 40 30.0 (15.8-44.2) 5.6
midodrine/octreotide 7 24 29.2 (11.0-47.4) 5.1
Silawat et al., 2011 [27] terlipressin 18 30 60.0 (42.5-77.5) 5.2
Narahara et al., 2012 [28] terlipressin 6 8 75.0 (45.0-100.0) 3.7
Singh et al., 2012 [29] terlipressin 9 23 39.1 (19.2-59.1) 4.9
noradrenaline 10 23 43.5 (23.2-63.7) 4.9
Tavakkoli et al., 2012 [30] midodrine/octreotide 7 9 77.8 (50.6-100.0) 4.0
noradrenaline 3 6 50.0 (10.0-90.0) 2.7
Total 230 525 49.5 (40.0-59.1) 100.0
Heterogeneity: I2, 75.3% (CI, 62.6-83.6%); p < 0.001
0 20 40 60 80 100
% HRS Reversal (CI)
Fig. 2 HRS reversal. Data points scaled in proportion to meta-analytic weight under a random effects model. Error bars represent CI. Abbreviations: CI,
95 % confidence interval; HRS, hepatorenal syndrome
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included in the meta-analysis were not specifically de-
signed as dose-ranging studies with head-to-head dose
comparisons, and there remains the possibility of con-
founding by variables reported either only infrequently or
not at all.
Furthermore, association does not imply causation.
Patients surviving longer might simply be receiving
higher cumulative albumin doses as a result. If so, it
could be expected that longer survival would be asso-
ciated with a more extended duration of treatment.
Study Vasoconstrictor Patient %s 30-Day Survival (CI) % Wgt.
Survivors Total
Angeli et al., 1999 [13] midodrine/octreotide 4 5 80.0 (51.6-100.0) 4.5
Mulkay et al., 2001 [15] terlipressin 10 12 83.3 (64.7-100.0) 7.3
Moreau et al., 2002 [16] terlipressin 37 99 37.1 (28.7-48.0) 10.2
Wong et al., 2004 [17] midodrine/octreotide 11 14 61.9 (34.5-100.0) 4.3
Alessandria et al., 2007 [18] terlipressin 4 5 80.0 (51.6-100.0) 4.5
noradrenaline 3 4 66.7 (30.0-100.0) 2.5
Neri et al., 2008 [20] terlipressin 20 26 72.5 (55.9-94.0) 7.9
Sanyal et al., 2008 [21] terlipressin 31 56 55.4 (43.8-70.0) 9.4
Sharma et al., 2008 [22] terlipressin 11 20 55.0 (37.0-81.8) 7.1
noradrenaline 11 20 55.0 (37.0-81.8) 7.1
Muñoz et al., 2009 [23] terlipressin 5 13 35.2 (16.2-76.1) 5.9
Skagen et al., 2009 [24] midodrine/octreotide 35 49 69.0 (56.6-84.1) 9.2
Narahara et al., 2012 [28] terlipressin 5 8 62.5 (36.5-100.0) 4.7
Singh et al., 2012 [29] terlipressin 8 23 32.0 (17.4-58.8) 7.7
noradrenaline 8 23 34.8 (19.9-60.9) 7.7
Total 203 377 50.6 (45.5-56.3) 100.0
Heterogeneity: I2, 67.4% (CI, 44.1-81.0%); p < 0.001
0 20 40 60 80 100
% 30-Day Survival (CI)
Fig. 3 Survival at 30 days. Graphic conventions as in Fig. 2. Abbreviation: CI, 95 % confidence interval
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However, that was not the case (Table 4). Additionally, it
could be expected that longer survival would be accom-
panied by larger cumulative doses of concurrent vaso-
constrictor. That also could not be detected (Table 4).
Thus, it appears unlikely that improved survival could
have caused larger cumulative albumin doses to be
administered.
The limitations of the studies assembled in this meta-
analysis arguably preclude evidence-based recommenda-
tions for clinical practice. Nonetheless, this meta-analysis
does furnish the best current evidence on an issue of
unequivocal clinical importance: whether patient sur-
vival might be improved by albumin dose optimization.
It is recognized that meta-analyses can play an import-
ant role in setting a clinical research agenda [7]. This
meta-analysis suggests the need for future albumin
dose-ranging studies. Furthermore, the meta-analysis
provides specific guidance in the design of such studies,
for instance, by identifying the range of cumulative al-
bumin doses over which effects on survival may vary.
In addition, the meta-analysis quantifies the magnitude
of likely treatment effects associated with varying albu-
min doses and would therefore be of value in sample
size computations for future studies.
The finding of a significant increase in short-term
survival among type 1 HRS patients with increasing cu-
mulative albumin dose is in accord with other studies
of cirrhotic patients showing survival benefits associ-
ated with albumin administration. The first such dem-
onstrated survival increase after albumin infusion was
in patients with cirrhosis and spontaneous bacterial
peritonitis (SBP) in 1999 [47]. A recent meta-analysis of
randomized trials in patients with SBP confirmed that
mortality was decreased by 66 % among the patients
who received albumin [48]. In a meta-analysis of ran-
domized trials among cirrhotic patients undergoing
large volume paracentesis, mortality was reduced by
36 % in those who received albumin compared to those
who received alternative treatments to improve circula-
tory function [49]. Finally, in a recent randomized trial
of patients with cirrhosis and episodic hepatic enceph-
alopathy, survival at 90 days was 69 % in those who re-
ceived albumin compared with 40 % of those who
received saline [50]. In summary, survival benefits of al-
bumin have now been documented in type 1 HRS, SBP,
large volume paracentesis, and hepatic encephalopathy.
These results point to the versatility of albumin as first-
line therapy for a range of serious complications in pa-
tients with decompensated cirrhosis.
Unlike the vasoconstrictors, adverse events attributable
to albumin infusion have been reported only very infre-
quently in the included and other studies, and these have
been related to pulmonary edema and/or circulatory over-
load [19, 28, 32]. Two included studies specifically reported
no adverse effects related to intravenous albumin adminis-
tration [22, 29]. Therefore while albumin infusion, even in
high total doses, appears to be well-tolerated in type 1 HRS
patients, nonetheless, monitoring of central venous pres-
sure directly by catheterization or indirectly by vena cava
ultrasound for signs of excessive cardiac preload may be a
prudent precaution, especially in patients receiving
higher cumulative albumin doses.
The pathophysiology of type 1 HRS is complex, but
pivotal to its onset is the marked reduction of effective
arterial blood volume resulting from blood volume re-
distribution into the splanchnic circulation and rela-
tively insufficient cardiac output [3]. This leads to renal
hypoperfusion caused by both reduced renal perfusion
pressure and renal vasoconstriction resulting from in-
creased activity of the renin-angiotensin-aldosterone
system (RAAS) and the sympathetic nervous system.
The hypovolemia of type 1 HRS patients is an ef-
fective not an absolute volume deficiency. A critical
amount of the circulating volume becomes pooled in
the enlarged splanchnic circulation because of increased
portal resistance to portal flow, excess production of a
number of endogenous vasodilators, most notably nitric
oxide (NO), and decreased responsiveness to endogen-
ous vasoconstrictors in that area. Pharmacologic ther-
apy with vasoconstrictors is thought to reverse HRS
primarily by working on the splanchnic vasculature to
redistribute part of the splanchnic volume back to the
systemic circulation.
The infusion of hyperoncotic 20 or 25 % albumin can
enhance and accelerate this redistribution by drawing
fluid into the central circulatory volume because of its
potent oncotic properties. Hyperoncotic albumin can
expand intravascular volume from 210 to 260 % of its
administered volume [51]. This small volume resuscita-
tion is advantageous in type 1 HRS patients because
they already carry a large fluid load and substantial fluid
infusion could potentially lead to worsening of ascites,
pleural effusion or heart failure [52, 53]. In addition, al-
bumin administration to cirrhotic patients with ascites
has been shown to result in markedly reduced plasma
renin activity, aldosterone levels and muscle sympa-
thetic nerve activity in a number of patient types with
ascites [54–56].
Since the endogenous albumin of patients with decom-
pensated cirrhosis is not only present at reduced levels,
but also is functionally impaired [57], the many functions
key to homeostasis that albumin performs are likely to be
compromised. Among albumin’s many other properties
are antioxidant, ligand-binding, immunomodulatory
and detoxification functions [58]. For instance, many
toxic substances present at elevated levels in decom-
pensated liver patients such as bilirubin, endotoxin, and
cytokines are bound and can be immunomodulated or
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detoxified by albumin. Albumin also binds to NO,
which plays a crucial role in the physiopathology of
HRS [59]. In a study of the effect of albumin on endo-
toxin removal, cytokines and NO production in pa-
tients with SBP, albumin administration significantly
reduced the levels of tumor necrosis factor-a (TNF-a)
and NO products in both plasma and ascitic fluid [60].
Another potential mechanism through which albumin
could benefit HRS patients is amelioration of the sys-
tolic dysfunction and chronotropic incompetence that
contributes to the pathogenesis of HRS [55]. Low cardiac
output predicts the development of HRS [61]. Albumin
infusion can increase the cardiac index in HRS patients
with refractory ascites [62]. In experimental cirrhosis of
rats, albumin exerted a positive cardiac inotropic effect
counteracting oxidative stress- and TNF-a-induced im-
pairment of cardiac contractility [63].
Conclusions
Despite treatment advances with vasoconstrictor and albu-
min, mortality among patients with type 1 HRS remains at
approximately 50 %. While clinical studies have focused on
the choice and optimization of vasoconstrictor, optimization
of the albumin regimen has not been pursued. This meta-
analysis suggests that albumin dose optimization may im-
prove outcome. However, further studies on the dose–re-
sponse relationship between infused albumin and HRS
reversal and survival in patients with type 1 HRS are both
warranted and needed to fully address this question.
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